(Q30446943)

19 August 2017

Repositioning of the anthelmintic drug mebendazole for the treatment for colon cancer (English)

1 reference

19 August 2017

1 reference

1 reference

1

Peter Nygren

1 reference

19 August 2017

4

Rolf Larsson

1 reference

19 August 2017

2

Mårten Fryknäs

1 reference

19 August 2017

Bengt Agerup

3

1 reference

19 August 2017

18 October 2013

1 reference

Journal of Cancer Research and Clinical Oncology

19 August 2017

1 reference

19 August 2017

139

1 reference

19 August 2017

12

1 reference

19 August 2017

2133-2140

1 reference

Creative Commons Attribution 2.0 Generic

19 August 2017

start time

18 October 2013

1 reference

April 2022 Public Data File from Crossref

copyright status

copyrighted

0 references

exact match

https://scigraph.springernature.com/pub.10.1007/s00432-013-1539-5

0 references

cites work

Antiproliferative effect of benzimidazole anthelmintics albendazole, ricobendazole, and flubendazole in intestinal cancer cell lines.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3825534

Computational drug repositioning: from data to therapeutics

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3825534

Comprehensive analysis of kinase inhibitor selectivity

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3825534

Antiparasitic mebendazole shows survival benefit in 2 preclinical models of glioblastoma multiforme

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3825534

How were new medicines discovered?

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3825534

New sources of drugs for hematologic malignancies

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3825534

PROMISCUOUS: a database for network-based drug-repositioning

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3825534

Cell line-based platforms to evaluate the therapeutic efficacy of candidate anticancer agents

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3825534

Novel trends in high-throughput screening

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3825534

Human cancer cell lines: Experimental models for cancer cells in situ? For cancer stem cells?

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3825534

The fluorometric microculture cytotoxicity assay

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3825534

Future of toxicology--iron chelators and differing modes of action and toxicity: the changing face of iron chelation therapy

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3825534

The Connectivity Map: using gene-expression signatures to connect small molecules, genes, and disease

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3825534

Antitumor activity of albendazole against the human colorectal cancer cell line HT-29: in vitro and in a xenograft model of peritoneal carcinomatosis

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3825534

A comparative study of albendazole and mebendazole-induced, time-dependent oxidative stress

20 June 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-013-1539-5

Pilot study of albendazole in patients with advanced malignancy. Effect on serum tumor markers/high incidence of neutropenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-013-1539-5

Nocodazole is a high-affinity ligand for the cancer-related kinases ABL, c-KIT, BRAF, and MEK.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-013-1539-5

In vitro and in vivo suppression of growth of hepatocellular carcinoma cells by albendazole

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-013-1539-5

Phase I clinical trial to determine maximum tolerated dose of oral albendazole in patients with advanced cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-013-1539-5

10.1007/S00432-013-1539-5

21 January 2018

Identifiers

DOI

1 reference

19 August 2017

1 reference

PMC publication ID

3825534

19 August 2017

PubMed publication ID

24135855

1 reference

PMC publication ID

3825534